Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

The setbacks include disappointing clinical trial results, a reduced US Food and Drug Administration (FDA) approval for its ...

Sage Therapeutics has said it will cut its headcount by 40% in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the FDA, with two of the company's founders ...

Sage Therapeutics and Biogen have a collaboration deal for the commercialization of Zurzuvae, which was approved for treating postpartum depression (PPD) in August 2023. The drug was commercially ...

Biogen will also make these resources available through a link on their Zurzuvae (zuranolone) patient website to help support women with PPD symptoms, in another example of the trend for pharma ...